Comparison

2’3’-c-di-AM(PS)2 (Rp,Rp) (disodium salt) European Partner

Item no. HY-12885A-25mg
Manufacturer MedChem Express
CASRN 1638750-95-4
Amount 25 mg
Quantity options 10 mg 1 mg 25 mg 50 mg 5 mg
Category
Type Inhibitors
Specific against other
Purity 99.91
Citations [1]Corrales L, et al. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity. Cell Rep. 2015 May 19;11(7):1018-30.
Acta Pharm Sin B. 2025 Mar;15(3):1211-1229.
Adv Sci (Weinh). 2024 Nov 19:e2407222.
Adv Sci (Weinh). 2025 Apr;12(16):e2414110.
bioRxiv. 2024 September 07.
Cancer Cell. 2024 May 13;42(5):850-868.e9.
Cell Death Dis. 2022 Jul 28;13(7):653.
Cell Rep Med. 2025 Jul 15;6(7):102239.
Chem Biodivers. 2024 Jul 12:e202401253.
Genes Dis. 2024 Sep 15;12(2):101434.
J Autoimmun. 2024 Jun:146:103232.
J Immunother Cancer. 2024 Oct 14;12(10):e009803.
Mol Ther. 2025 Sep 22:S1525-0016(25)00761-0.
Nat Cell Biol. 2024 Sep;26(9):1585-1596.
Nat Commun. 2023 Oct 2;14(1):6132.
Sci China Life Sci. 2024 Dec;67(12):2664-2677.
ACS Appl Mater Interfaces. 2025 Feb 5;17(5):7395-7405.
ACS Appl Mater Interfaces. 2025 Oct 15;17(41):56832-56845.
Acta Crystallogr D Struct Biol. 2020 Sep 1;76(Pt 9):889-898.
Adv Funct Mater. 2025 Nov 11.
bioRxiv. 2024 May 14.
Cancer Cell. 2023 Jun 12;41(6):1073-1090.e12.
Cancer Res Commun. 2024 Jan 16;4(1):118-133.
Cell Biol Toxicol. 2025 May 7;41(1):82.
Cell Commun Signal. 2025 Feb 19;23(1):99.
Cell Mol Gastroenterol Hepatol. 2021;12(1):41-58.
Cell Mol Immunol. 2025 Dec;22(12):1549-1566.
Cell Signal. 2025 Jun 16:111948.
Environ Int. 2020 Oct;143:105949.
Eur J Med Chem. 2023 Mar 15:250:115184.
Front Immunol. 2021 Jul 1:12:695056.
Front Immunol. 2023 Oct 13:14:1258691.
Immunology. 2022 Dec;167(4):495-507.
Inflamm Res. 2023 Aug;72(8):1551-1565.
Int J Mol Sci. 2023 Dec 20;25(1):86.
J Control Release. 2025 Jan 14:379:327-343.
J Immunother Cancer. 2019 Sep 18;7(1):252. 
J Neuroinflammation. 2023 Apr 30;20(1):101.
J Pharm Sci. 2025 Nov 17:104065.
Mol Cell Biochem. 2021 Feb;476(2):1015-1024.
Nat Commun. 2023 Mar 13;14(1):1390.
Nat Commun. 2023 Sep 18;14(1):5666.
Nat Commun. 2024 Nov 15;15(1):9934.
Nat Immunol. 2025 Oct;26(10):1766-1780.
Nat Nanotechnol. 2021 Nov;16(11):1260-1270.
Neuron. 2023 Jan 18;111(2):236-255.e7.
Oncoimmunology. 2025 Dec;14(1):2466305.
Patent. US20200146975A1
Patent. US20210205468A1.
Patent. US20230062932A1.
Patent. US20250221932A1.
Patent. US20250276085A1.
Purdue University. 2024 Jul 20.
Research Square Preprint. 2022 Feb.
Research Square Preprint. 2022 Jan.
Research Square Preprint. 2024 Apr 5.
University of Toronto. 2023 Jun.
Wayne State University. 2024.
Biomaterials. 2018 May;163:67-75.
bioRxiv. 2024 Jan 23.
bioRxiv. 2024 September 20.
bioRxiv. October 23, 2021.
Cancer Cell. 2020 Mar 16;37(3):289-307.e9. 
Commun Biol. 2021 Apr 22;4(1):497.
Eur J Med Chem. 2022 Dec 5:243:114796.
J Clin Invest. 2024 Mar 19;134(10):e176748.
J Interferon Cytokine Res. 2025 Jan;45(1):29-37.
Mater Today Bio. 2024 Mar 11:26:101018.
Nat Commun. 2022 May 31;13(1):3022.
Nature. 2023 Apr;616(7958):806-813.
Patent. US20210322327A1.
Patent. US20220162199A1.
Patent. US20220395465A1.
PLoS One. 2020 Sep 10;15(9):e0237743.
University of Pittsburgh. School of Medicine. 2021 May 14.
Smiles O[C@H]1[C@@H](O[P@@](OC[C@H]2O[C@@H](N3C(N=CN=C4N)=C4N=C3)[C@H](O)[C@@H]2O5)(S[Na])=O)[C@H](N6C(N=CN=C7N)=C7N=C6)O[C@@H]1CO[P@]5(S[Na])=O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias ADU-S100 (disodium salt),MIW815 (disodium salt),ML RR-S2 CDA (disodium salt)
Shipping Condition Cool pack
Available
Manufacturer - Type
Reference compound
Manufacturer - Applications
COVID-19-immunoregulation
Manufacturer - Category
Reference compound / Active compounds
Manufacturer - Targets
STING
Manufacturer - HS Code
H302, H315, H319
Shipping Temperature
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture and light)
Molecular Weight
734.51
Product Description
2’3’-c-di-AM(PS)2 (Rp, Rp) disodium salt (ADU-S100 disodium salt) is an activator of stimulator of interferon genes (STING).
Manufacturer - Research Area
Inflammation/Immunology; Cancer
Solubility
H2O : 100 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway
Immunology/Inflammation
Clinical information
Phase 2
UNSPSC Code
12352005
Precautionary
H302, H315, H319

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?